Skip to content

US · CNSY · MEDICAL - PHARMACEUTICALS

Cerenome, Inc. (CNSY) intrinsic value and stock valuation

$2.03as of 2026-09-18 · Mkt cap 14.04M

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cerenome, Inc. DCF and intrinsic value

InvestorsCraft values CNSY with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CNSY’s statements →

Cerenome, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Pharmaceuticals Houston, TX, US plustherapeutics.com

How the business is doing

Fiscal 2025–1998, USD

Revenue
$0.00
20251998
Net income
-$-2.09T
20251998
Free cash flow
-$-1.52T
20251998
Total equity
$108B-62.7% 5y CAGRd
20251998

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–1998, USD
FYFYFYFYFY
Revenue$5.21T$5.82T$4.91T$224B$0.00
Operating income-$-15.3T-$-14.7T-$-13.32T-$-19.71T-$-12.49T
Net income-$-22.39T-$-12.98T-$-13.32T-$-20.28T-$-13.4T
EPSd-$-7.19M-$-42.13M-$-105.99B-$-289.58B-$-415.63B
Operating cash flow-$-20.78T-$-10.55T-$-12.85T-$-12.97T-$-10.28T
Capital expenditure-$-67B-$-146B-$-160B-$-759B-$-144B
Free cash flow-$-20.84T-$-10.7T-$-13.01T-$-13.73T-$-10.42T
Total assets$16.3T$6.63T$11.4T$23.9T$22T
Total debt$821B$3.37T$4.18T$5.76T$6.99T
Net debt-$-7.94T$3.29T-$-4.37T-$-12.37T-$-11.41T
Total equity$4T-$-8.95T-$-1.35T$6.45T$10.8T
Cash and short-term investments$8.76T$3.61T$8.55T$18.1T$18.4T
Income statement
FYFYFYFYFY
Revenue$5.21T$5.82T$4.91T$224B$0.00
Cost of revenue$445B$852B$9.69T$712B$66B
Gross profit$4.77T$4.97T-$-4.78T-$-488B-$-66B
Research and development expenses$8.38T$10.6T$9.69T$9.7T$5.32T
Selling, general and administrative expenses$12.1T$9.94T$8.54T$9.53T$6.85T
Other expenses-$-445B-$-852B-$-9.69T$0.00$250B
Operating expenses$20.1T$19.7T$8.54T$19.2T$12.4T
Cost and expenses$20.5T$20.5T$18.2T$19.9T$12.5T
Interest income$116B$273B$400B$147B$19B
Interest expense$3.61T$3.72T$395B$711B$932B
Depreciation and amortization$445B$852B$628B$712B$419B
Ebitda-$-18.33T-$-8.4T-$-12.29T-$-18.85T-$-12.05T
Operating income-$-15.3T-$-14.7T-$-13.32T-$-19.71T-$-12.49T
Total other income/expenses, net-$-7.09T$1.72T$5B-$-563B-$-907B
Income before tax-$-22.39T-$-12.98T-$-13.32T-$-20.28T-$-13.4T
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-22.39T-$-12.98T-$-13.32T-$-20.28T-$-13.4T
Weighted average shares outstanding$3.11T$265.6B$125.6M$70M$32.2M
Weighted average diluted shares outstanding$3.11T$308B$125.6M$70M$32.2M
Balance sheet
FYFYFYFYFY
Cash and short-term investments$8.76T$3.61T$8.55T$18.1T$18.4T
Net receivables$0.00$571B$0.00$0.00$7B
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$15.2T$5.26T$9.83T$21.8T$19.7T
Property, plant and equipment, net$327B$521B$1.11T$1.57T$1.82T
Goodwill and intangible assets$705B$841B$414B$466B$423B
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.16T$1.37T$1.55T$2.05T$2.26T
Total assets$16.3T$6.63T$11.4T$23.9T$22T
Accounts payable$3.28T$9.47T$4.76T$8.36T$2.61T
Short-term debt$806B$3.34T$4.1T$1.83T$1.72T
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$12.3T$15.6T$10.7T$11.9T$5.87T
Long-term debt$15B$31B$85B$3.93T$5.27T
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$15B$31B$2.01T$5.57T$5.28T
Capital lease obligations$0.00$75B$205B$251B$380B
Total liabilities$12.3T$15.6T$12.7T$17.4T$11.1T
Common stock$139B$6B$5B$34B$16B
Retained earnings-$-515.87T-$-493.48T-$-480.5T-$-467.19T-$-446.91T
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$4T-$-8.95T-$-1.35T$6.45T$10.8T
Total investments$0.00$3.53T$0.00$0.00$0.00
Total debt$821B$3.37T$4.18T$5.76T$6.99T
Net debt-$-7.94T$3.29T-$-4.37T-$-12.37T-$-11.41T
Cash flow statement
FYFYFYFYFY
Net income-$-22.39T-$-12.98T-$-13.32T-$-20.28T-$-13.4T
Depreciation and amortization$445B$723B$628B$619B$395B
Stock-based compensation$1.54T$550B$569B$606B$606B
Change in working capital-$-6.04T$3.22T-$-1.12T$5.6T$1.24T
Accounts receivable$249B-$-571B$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-5.62T$4.7T-$-3.68T$0.00$1.73T
Net cash provided by operating activities-$-20.78T-$-10.55T-$-12.85T-$-12.97T-$-10.28T
Investments in property, plant and equipment-$-67B-$-146B-$-160B-$-509B-$-144B
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-854B-$-4.11T-$-160B-$-759B-$-82B
Common stock issued$15.7T$7.27T$5.53T$15.8T$18.7T
Common stock repurchased$0.00-$-374B-$-126B$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$30.3T$6.19T$3.45T$13.5T$20.4T
Net change in cash$8.68T-$-8.48T-$-9.57T-$-280B$10.1T
Cash at end of period$8.76T$76B$8.55T$18.1T$18.4T
Operating cash flow-$-20.78T-$-10.55T-$-12.85T-$-12.97T-$-10.28T
Capital expenditure-$-67B-$-146B-$-160B-$-759B-$-144B
Free cash flow-$-20.84T-$-10.7T-$-13.01T-$-13.73T-$-10.42T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cerenome, Inc.

        Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

        CEO
        Marc H. Hedrick
        Employees
        28
        Beta
        1.39

        Explore

        Frequently asked questions

        What is the intrinsic value of Cerenome, Inc. (CNSY)?

        InvestorsCraft does not currently publish an intrinsic value for CNSY. How the IC value is calculated.

        Is CNSY undervalued?

        InvestorsCraft does not publish an undervaluation signal for CNSY at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.